Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Other Accumulated Expenses (2019 - 2025)

IDEAYA Biosciences' Other Accumulated Expenses history spans 7 years, with the latest figure at $32.9 million for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses changed N/A year-over-year to $32.9 million; the TTM value through Sep 2025 reached $32.9 million, changed N/A, while the annual FY2024 figure was $950000.0, 91.1% down from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $32.9 million at IDEAYA Biosciences, up from $628000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $32.9 million in Q3 2025 and bottomed at $17000.0 in Q2 2024.
  • The 5-year median for Other Accumulated Expenses is $947500.0 (2023), against an average of $6.1 million.
  • The largest annual shift saw Other Accumulated Expenses soared 27017.24% in 2021 before it plummeted 98.83% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $7.9 million in 2021, then tumbled by 98.83% to $92000.0 in 2022, then soared by 11504.35% to $10.7 million in 2023, then tumbled by 91.1% to $950000.0 in 2024, then skyrocketed by 3360.84% to $32.9 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Other Accumulated Expenses are $32.9 million (Q3 2025), $628000.0 (Q2 2025), and $630000.0 (Q1 2025).